NCT03819777

Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)

Volatile Organic Compounds as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Maastricht University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds. Hypothesis: first, the investigators hypothesize that at time of diagnosis the VOC profiles will discriminate patients with PAH-CTD and idiopathic PAH (IPAH) from patients with systemic sclerosis or systemic lupus erythematosus (CTD) without PAH, supporting the contention that there is a overlapping inflammatory and auto-immune pathway in PAH. During follow-up, the investigators will measure the VOC profiles of patients in all three groups who will be treated according standard clinical care. The hypothesis is that VOC profiles are affected by therapy.

Conditions

• Pulmonary Arterial Hypertension
• Systemic Sclerosis
• Systemic Lupus

Timeline

• Start date: 2018-03-01
• Primary completion: 2022-10-31
• Completion: 2023-01-31
• First posted: 2019-01-29
• Last updated: 2021-09-08

Locations

1 site across 1 country: Netherlands